{"retracted":false,"update":{"timestamp":1417478400000,"doi":"10.1007/s00280-014-2625-3","type":"correction"},"doi":"10.1007/s00280-014-2609-3","journal":"Cancer Chemotherapy and Pharmacology","publisher":"Springer Nature","title":"Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer"}
